Press releases

Callavid intravaginal drug delivery platform selected to advance targeted UTI treatment as part of new programme addressing antibiotic-driven antimicrobial resistance London, UK – Calla Lily Clinical Care, a women’s health-focused medical technology company, today announced it has joined Wellcome Leap’s Focused Antibiotics programme – a new $50M funded programme to transform how antibiotics are delivered …

FREEDOM study to evaluate progesterone delivery using Callavid intravaginal platform NIHR-funded trial in collaboration with University Hospitals Coventry and Warwickshire NHS Trust London, UK – Calla Lily Clinical Care, a women’s health-focused medical technology company, today announced dosing of the first patients in the FREEDOM clinical trial. The study, funded by the National Institute for …

London, UK – Calla Lily Clinical Care, a women’s health-focused medical technology company, and Merck, a leading science and technology company, have entered a strategic collaboration to support the continued development of Callavid®, a novel platform for intravaginal drug delivery. The collaboration represents the first industry partnership for the Callavid® technology. Callavid is a transformational leak-resistant …

London, UK – A team of scientists and biomedical engineers developing pioneering technology designed to treat threatened miscarriage has secured £1 million in Invention for Innovation (i4i) funding from the National Institute for Health and Care Research (NIHR) for its first clinical trial. The new technology is a novel device designed to improve the delivery …